Gala vs Oak Longevity: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

53 providers verified independently·Independent research·How we rank →

Visit Oak Longevity - our pick of these two→or find your match

Oak Longevity beats Gala overall, scoring 7.5/10 vs 7.2/10. Oak Longevity is more affordable at $133/mo vs $149/mo. Choose Gala for tirzepatide-first patients who want a low-cost compounded pa. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.

A side-by-side look at Gala and Oak Longevity to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Gala

#39 of 53

7.2/10

Telehealth platform focused on compounded tirzepatide, both microdose and full-dose tiers, alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.

Visit Gala

Higher Rated

Oak Longevity

#25 of 53

7.5/10

Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing, patients pay each month manually rather than auto-renew.

Visit Oak Longevity

Feature	Gala	Oak Longevity
Our Score	7.2/10	7.5/10
Starting Price	$149/mo	$133/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated iOS + Android tracker app for daily progress logging	Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin)
Watch out for	Brand-name Ozempic here is $1,299/mo, materially above market (NovoCare direct pricing for Wegovy is $349/mo; Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership). Buy brand-name elsewhere, Gala's value is its compounded tirzepatide.	Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct
Ranking	#39	#25
Get started	Visit Gala	Visit Oak Longevity

Pros & Cons Compared

Gala

Pros

+Microdose compounded tirzepatide at $149/mo, the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
+Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android, first-party in-treatment logging is uncommon among compounded-only platforms
+OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
+All 50 states, free shipping, no insurance required, 24/7 patient support claimed

Cons

−Brand-name Ozempic here is $1,299/mo, materially above market (NovoCare direct pricing for Wegovy is $349/mo; Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership). Buy brand-name elsewhere, Gala's value is its compounded tirzepatide.
−Tirzepatide-only on the compounded side, compounded semaglutide is NOT offered, a narrower medication menu than peers like Maximus, Ro, or Henry Meds
−Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness, verify your specific dose and batch with each refill
−Initial consultation is typically a sync video visit, but ongoing follow-ups are chat-based (no scheduled ongoing video access), and there are no published labs, no named medical director, no specialty obesity oversight
−Restrictive refund policy, Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
−Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn), limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself

Oak Longevity

Pros

+$133/mo for compounded semaglutide is among the cheapest entries on the market, Sesame Care ($99) is lower, but Oak undercuts most mid-tier platforms
+No-subscription model, patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
+Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
+Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
+Money-back guarantee if not approved by physician, useful safety net for borderline-eligibility patients
+Free shipping and free health coaching included in every program

Cons

−Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct
−No published lab panels and no specialty (obesity medicine) physicians disclosed, clinical oversight is lighter than lab-driven platforms
−The 'up to 50% cheaper than competitors' marketing claim is unverified and inconsistent, judge Oak on its posted prices, which are genuinely low, not on the slogan
−The longevity add-ons (NAD+, Sermorelin, Tesamorelin) have limited clinical evidence for weight loss specifically, if weight loss is the goal, the GLP-1 alone does the work and the stack is optional
−Newer brand without disclosed company history, founding date, or executive team on landing pages
−Three-month plans are billed upfront, start on the 1-month plan if you're testing the platform, then bundle once it fits

Our Verdict

Oak Longevity edges out Gala with a score of 7.5/10 vs 7.2/10. If budget is your priority, Oak Longevity starts at $133/mo compared to Gala's $149/mo. Choose Gala if you want: tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither Gala nor Oak Longevity feels like the right fit, our featured pick across all 53 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Visit TrimRx→Read our full TrimRx review